Literature DB >> 21512139

Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis.

Nathan P Young1, Denise Crowley, Tyler Jacks.   

Abstract

It is well accepted that cancer develops following the sequential accumulation of multiple alterations, but how the temporal order of events affects tumor initiation and/or progression remains largely unknown. Here, we describe a mouse model that allows for temporally distinct cancer mutations. By integrating a Flp-inducible allele of K-ras(G12D) with established methods for Cre-mediated p53 deletion, we were able to separately control the mutation of these commonly associated cancer genes in vitro and in vivo. We show that delaying p53 deletion relative to K-ras(G12D) activation reduced tumor burden in a mouse model of soft-tissue sarcoma, suggesting that p53 strongly inhibits very early steps of transformation in the muscle. Furthermore, using in vivo RNA interference, we implicate the p53 target gene p21 as a critical mediator in this process, highlighting cell-cycle arrest as an extremely potent tumor suppressor mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512139      PMCID: PMC3160277          DOI: 10.1158/0008-5472.CAN-10-4563

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

2.  A spatially and temporally restricted mouse model of soft tissue sarcoma.

Authors:  David G Kirsch; Daniela M Dinulescu; John B Miller; Jan Grimm; Philip M Santiago; Nathan P Young; G Petur Nielsen; Bradley J Quade; Christopher J Chaber; Christian P Schultz; Osamu Takeuchi; Roderick T Bronson; Denise Crowley; Stanley J Korsmeyer; Sam S Yoon; Francis J Hornicek; Ralph Weissleder; Tyler Jacks
Journal:  Nat Med       Date:  2007-08-05       Impact factor: 53.440

3.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 4.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

6.  Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression.

Authors:  A Efeyan; M Collado; S Velasco-Miguel; M Serrano
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

7.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.

Authors:  M A Christophorou; I Ringshausen; A J Finch; L Brown Swigart; G I Evan
Journal:  Nature       Date:  2006-09-06       Impact factor: 49.962

Review 8.  Tumors associated with p53 germline mutations: a synopsis of 91 families.

Authors:  P Kleihues; B Schäuble; A zur Hausen; J Estève; H Ohgaki
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 9.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells.

Authors:  Christopher S Raymond; Philippe Soriano
Journal:  PLoS One       Date:  2007-01-17       Impact factor: 3.240

View more
  49 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors:  Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

3.  Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression.

Authors:  G Y Wang; C N Wood; J A Dolorito; E Libove; E H Epstein
Journal:  Oncogene       Date:  2017-03-06       Impact factor: 9.867

4.  Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials.

Authors:  Cory Abate-Shen; Pier Paolo Pandolfi
Journal:  Cold Spring Harb Protoc       Date:  2013-11-01

5.  TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Authors:  Anny Shai; David Dankort; Joseph Juan; Shon Green; Martin McMahon
Journal:  Cancer Res       Date:  2015-05-22       Impact factor: 12.701

6.  The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Authors:  Gurkan Mollaoglu; Alex Jones; Sarah J Wait; Anandaroop Mukhopadhyay; Sangmin Jeong; Rahul Arya; Soledad A Camolotto; Timothy L Mosbruger; Chris J Stubben; Christopher J Conley; Arjun Bhutkar; Jeffery M Vahrenkamp; Kristofer C Berrett; Melissa H Cessna; Thomas E Lane; Benjamin L Witt; Mohamed E Salama; Jason Gertz; Kevin B Jones; Eric L Snyder; Trudy G Oliver
Journal:  Immunity       Date:  2018-10-16       Impact factor: 31.745

7.  p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.

Authors:  Yong Ding; Yucai Wang; Jun Chen; Yunsheng Hu; Zhuo Cao; Pengcheng Ren; Yong Zhang
Journal:  Tumour Biol       Date:  2013-12-11

8.  p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.

Authors:  Phillippe P Gonzalez; Jungeun Kim; Rui Pedro Galvao; Nichola Cruickshanks; Roger Abounader; Hui Zong
Journal:  Glia       Date:  2018-02-02       Impact factor: 7.452

9.  Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy.

Authors:  Everett J Moding; Katherine D Castle; Bradford A Perez; Patrick Oh; Hooney D Min; Hannah Norris; Yan Ma; Diana M Cardona; Chang-Lung Lee; David G Kirsch
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

10.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.

Authors:  Eric L Snyder; Hideo Watanabe; Margaret Magendantz; Sebastian Hoersch; Tiffany A Chen; Diana G Wang; Denise Crowley; Charles A Whittaker; Matthew Meyerson; Shioko Kimura; Tyler Jacks
Journal:  Mol Cell       Date:  2013-03-21       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.